vs
Orthofix Medical Inc.（OFIX）与UNIVERSAL DISPLAY CORP \PA\（OLED）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是UNIVERSAL DISPLAY CORP \PA\的1.3倍（$219.9M vs $172.9M），UNIVERSAL DISPLAY CORP \PA\净利率更高（38.4% vs -1.0%，领先39.4%），UNIVERSAL DISPLAY CORP \PA\同比增速更快（6.6% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $15.1M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 2.3%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Universal Display Corporation（股票代码OLED）是有机发光二极管（OLED）技术及材料的研发与生产企业，拥有深厚的技术积累，面向显示、照明两大领域提供相关配套服务，是全球OLED上游产业链的核心供应商之一。
OFIX vs OLED — 直观对比
营收规模更大
OFIX
是对方的1.3倍
$172.9M
营收增速更快
OLED
高出4.6%
2.0%
净利率更高
OLED
高出39.4%
-1.0%
自由现金流更多
OFIX
多$1.8M
$15.1M
两年增速更快
OFIX
近两年复合增速
2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $172.9M |
| 净利润 | $-2.2M | $66.3M |
| 毛利率 | 71.1% | 76.1% |
| 营业利润率 | 0.2% | 38.9% |
| 净利率 | -1.0% | 38.4% |
| 营收同比 | 2.0% | 6.6% |
| 净利润同比 | 92.4% | 44.2% |
| 每股收益（稀释后） | $-0.05 | $1.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXOLED
| Q4 25 | $219.9M | $172.9M | ||
| Q3 25 | $205.6M | $139.6M | ||
| Q2 25 | $203.1M | $171.8M | ||
| Q1 25 | $193.6M | $166.3M | ||
| Q4 24 | $215.7M | $162.3M | ||
| Q3 24 | $196.6M | $161.6M | ||
| Q2 24 | $198.6M | $158.5M | ||
| Q1 24 | $188.6M | $165.3M |
净利润OFIXOLED
| Q4 25 | $-2.2M | $66.3M | ||
| Q3 25 | $-22.8M | $44.0M | ||
| Q2 25 | $-14.1M | $67.3M | ||
| Q1 25 | $-53.1M | $64.4M | ||
| Q4 24 | $-29.1M | $46.0M | ||
| Q3 24 | $-27.4M | $66.9M | ||
| Q2 24 | $-33.4M | $52.3M | ||
| Q1 24 | $-36.0M | $56.9M |
毛利率OFIXOLED
| Q4 25 | 71.1% | 76.1% | ||
| Q3 25 | 72.2% | 74.6% | ||
| Q2 25 | 68.7% | 77.2% | ||
| Q1 25 | 62.8% | 77.1% | ||
| Q4 24 | 69.0% | 77.0% | ||
| Q3 24 | 68.7% | 77.8% | ||
| Q2 24 | 67.8% | 75.8% | ||
| Q1 24 | 67.5% | 77.6% |
营业利润率OFIXOLED
| Q4 25 | 0.2% | 38.9% | ||
| Q3 25 | -8.3% | 30.9% | ||
| Q2 25 | -7.9% | 39.9% | ||
| Q1 25 | -25.2% | 41.9% | ||
| Q4 24 | -5.3% | 32.3% | ||
| Q3 24 | -9.6% | 41.5% | ||
| Q2 24 | -12.5% | 35.6% | ||
| Q1 24 | -15.6% | 38.0% |
净利率OFIXOLED
| Q4 25 | -1.0% | 38.4% | ||
| Q3 25 | -11.1% | 31.5% | ||
| Q2 25 | -6.9% | 39.2% | ||
| Q1 25 | -27.4% | 38.8% | ||
| Q4 24 | -13.5% | 28.4% | ||
| Q3 24 | -13.9% | 41.4% | ||
| Q2 24 | -16.8% | 33.0% | ||
| Q1 24 | -19.1% | 34.4% |
每股收益（稀释后）OFIXOLED
| Q4 25 | $-0.05 | $1.40 | ||
| Q3 25 | $-0.57 | $0.92 | ||
| Q2 25 | $-0.36 | $1.41 | ||
| Q1 25 | $-1.35 | $1.35 | ||
| Q4 24 | $-0.76 | $0.96 | ||
| Q3 24 | $-0.71 | $1.40 | ||
| Q2 24 | $-0.88 | $1.10 | ||
| Q1 24 | $-0.95 | $1.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $602.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $1.8B |
| 总资产 | $850.6M | $2.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXOLED
| Q4 25 | $82.0M | $602.4M | ||
| Q3 25 | $62.9M | $603.0M | ||
| Q2 25 | $65.6M | $525.2M | ||
| Q1 25 | $58.0M | $571.3M | ||
| Q4 24 | $83.2M | $492.7M | ||
| Q3 24 | $30.1M | $551.6M | ||
| Q2 24 | $26.4M | $530.5M | ||
| Q1 24 | $27.0M | $539.3M |
总债务OFIXOLED
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXOLED
| Q4 25 | $450.0M | $1.8B | ||
| Q3 25 | $442.5M | $1.7B | ||
| Q2 25 | $458.3M | $1.7B | ||
| Q1 25 | $458.3M | $1.7B | ||
| Q4 24 | $503.1M | $1.6B | ||
| Q3 24 | $525.9M | $1.6B | ||
| Q2 24 | $546.0M | $1.5B | ||
| Q1 24 | $570.3M | $1.5B |
总资产OFIXOLED
| Q4 25 | $850.6M | $2.0B | ||
| Q3 25 | $832.6M | $1.9B | ||
| Q2 25 | $837.2M | $1.9B | ||
| Q1 25 | $823.1M | $1.9B | ||
| Q4 24 | $893.3M | $1.8B | ||
| Q3 24 | $867.9M | $1.8B | ||
| Q2 24 | $882.0M | $1.8B | ||
| Q1 24 | $906.0M | $1.7B |
负债/权益比OFIXOLED
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $31.1M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $15.1M |
| 自由现金流率自由现金流/营收 | 7.6% | 8.7% |
| 资本支出强度资本支出/营收 | 4.9% | 9.3% |
| 现金转化率经营现金流/净利润 | — | 0.47× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $154.4M |
8季度趋势，按日历期对齐
经营现金流OFIXOLED
| Q4 25 | $27.7M | $31.1M | ||
| Q3 25 | $12.4M | $97.2M | ||
| Q2 25 | $11.6M | $51.9M | ||
| Q1 25 | $-18.4M | $30.6M | ||
| Q4 24 | $23.7M | $34.7M | ||
| Q3 24 | $11.7M | $79.9M | ||
| Q2 24 | $9.0M | $67.0M | ||
| Q1 24 | $-18.6M | $72.2M |
自由现金流OFIXOLED
| Q4 25 | $16.8M | $15.1M | ||
| Q3 25 | $2.5M | $84.3M | ||
| Q2 25 | $4.5M | $37.5M | ||
| Q1 25 | $-25.1M | $17.5M | ||
| Q4 24 | $15.2M | $22.0M | ||
| Q3 24 | $6.3M | $66.2M | ||
| Q2 24 | $-360.0K | $57.9M | ||
| Q1 24 | $-29.1M | $65.0M |
自由现金流率OFIXOLED
| Q4 25 | 7.6% | 8.7% | ||
| Q3 25 | 1.2% | 60.4% | ||
| Q2 25 | 2.2% | 21.8% | ||
| Q1 25 | -13.0% | 10.5% | ||
| Q4 24 | 7.0% | 13.6% | ||
| Q3 24 | 3.2% | 41.0% | ||
| Q2 24 | -0.2% | 36.5% | ||
| Q1 24 | -15.4% | 39.3% |
资本支出强度OFIXOLED
| Q4 25 | 4.9% | 9.3% | ||
| Q3 25 | 4.8% | 9.2% | ||
| Q2 25 | 3.5% | 8.4% | ||
| Q1 25 | 3.5% | 7.9% | ||
| Q4 24 | 4.0% | 7.8% | ||
| Q3 24 | 2.7% | 8.4% | ||
| Q2 24 | 4.7% | 5.8% | ||
| Q1 24 | 5.6% | 4.4% |
现金转化率OFIXOLED
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | 2.21× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | 1.19× | ||
| Q2 24 | — | 1.28× | ||
| Q1 24 | — | 1.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
OLED
| Material Sales | $95.5M | 55% |
| Other | $72.6M | 42% |
| Contract Research Services | $4.8M | 3% |
